Literature DB >> 26538999

Correlation between Drug Market Withdrawals and Socioeconomic, Health, and Welfare Indicators Worldwide.

Kye Hwa Lee1, Grace Juyun Kim1, Ju Han Kim1.   

Abstract

The relationship between the number of withdrawn/restricted drugs and socioeconomic, health, and welfare indicators were investigated in a comprehensive review of drug regulation information in the United Nations (UN) countries. A total of of 362 drugs were withdrawn and 248 were restricted during 1950-2010, corresponding to rates of 12.02 ± 13.07 and 5.77 ± 8.69 (mean ± SD), respectively, among 94 UN countries. A socioeconomic, health, and welfare analysis was performed for 33 OECD countries for which data were available regarding withdrawn/restricted drugs. The gross domestic product (GDP) per capita, GDP per hour worked, health expenditure per GDP, and elderly population rate were positively correlated with the numbers of withdrawn and restricted drugs (P < 0.05), while the out-of-pocket health expenditure payment rate was negatively correlated. The number of restricted drugs was also correlated with the rate of drug-related deaths (P < 0.05). The World Bank data cross-validated the findings of 33 OECD countries. The lists of withdrawn/restricted drugs showed markedly poor international agreement between them (Fleiss's kappa = -0.114). Twenty-seven drugs that had been withdrawn internationally by manufacturers are still available in some countries. The wide variation in the numbers of drug withdrawals and restrictions among countries indicates the need to improve drug surveillance systems and regulatory communication networks.

Entities:  

Keywords:  Health Expenditures; Organization for Economic Cooperation and Development; Postmarketing; Product Recalls and Withdrawals; Product Surveillance; Socioeconomic Factors

Mesh:

Year:  2015        PMID: 26538999      PMCID: PMC4630471          DOI: 10.3346/jkms.2015.30.11.1567

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  10 in total

1.  The safety of newly approved medicines: do recent market removals mean there is a problem?

Authors:  M A Friedman; J Woodcock; M M Lumpkin; J E Shuren; A E Hass; L J Thompson
Journal:  JAMA       Date:  1999-05-12       Impact factor: 56.272

2.  Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project.

Authors:  Preciosa M Coloma; Martijn J Schuemie; Gianluca Trifirò; Rosa Gini; Ron Herings; Julia Hippisley-Cox; Giampiero Mazzaglia; Carlo Giaquinto; Giovanni Corrao; Lars Pedersen; Johan van der Lei; Miriam Sturkenboom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11-08       Impact factor: 2.890

3.  Lessons from the withdrawal of rofecoxib.

Authors:  Paul A Dieppe; Shah Ebrahim; Richard M Martin; Peter Jüni
Journal:  BMJ       Date:  2004-10-16

4.  A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.

Authors:  John Abraham; Courtney Davis
Journal:  Soc Sci Med       Date:  2005-03-02       Impact factor: 4.634

5.  Developing the Sentinel System--a national resource for evidence development.

Authors:  Rachel E Behrman; Joshua S Benner; Jeffrey S Brown; Mark McClellan; Janet Woodcock; Richard Platt
Journal:  N Engl J Med       Date:  2011-01-12       Impact factor: 91.245

6.  Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.

Authors:  O M Bakke; M Manocchia; F de Abajo; K I Kaitin; L Lasagna
Journal:  Clin Pharmacol Ther       Date:  1995-07       Impact factor: 6.875

Review 7.  Management of thalidomide toxicity.

Authors:  Irene M Ghobrial; S Vincent Rajkumar
Journal:  J Support Oncol       Date:  2003 Sep-Oct

8.  Understanding the rapid increase in life expectancy in South Korea.

Authors:  Seungmi Yang; Young-Ho Khang; Sam Harper; George Davey Smith; David A Leon; John Lynch
Journal:  Am J Public Health       Date:  2010-03-18       Impact factor: 9.308

9.  Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.

Authors:  Igho J Onakpoya; Carl J Heneghan; Jeffrey K Aronson
Journal:  BMC Med       Date:  2015-02-05       Impact factor: 8.775

10.  A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples.

Authors:  Logyoung Kim; Jee-Ae Kim; Sanghyun Kim
Journal:  Epidemiol Health       Date:  2014-07-30
  10 in total
  1 in total

1.  Withdrawn medicines included in the essential medicines lists of 136 countries.

Authors:  Onella Charles; Igho Onakpoya; Simran Benipal; Hannah Woods; Anjli Bali; Jeffrey K Aronson; Carl Heneghan; Nav Persaud
Journal:  PLoS One       Date:  2019-12-02       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.